Title

人類微小病毒B19-VP1u蛋白對Balb/c小鼠肝臟影響之探討

Translated Titles

Study of Human Parvovirus B19-VP1u Proteins on Liver of Balb/c Mice

DOI

10.6834/CSMU.2013.00069

Authors

張舜智

Key Words

人類微小病毒B19 ; 肝臟 ; VP1u ; 活體影像系統 ; Human Parvovirus B19 ; Liver ; VP1u ; IVIS

PublicationName

中山醫學大學生化微生物免疫研究所學位論文

Volume or Term/Year and Month of Publication

2013年

Academic Degree Category

碩士

Advisor

徐再靜

Content Language

繁體中文

Chinese Abstract

人類微小病毒B19是微小病毒科中可以感染人類並且致病的病毒。過去研究證據顯示肝臟疾病患者之血液或是肝臟組織中有B19病毒蹤影,許多文獻也指出感染B19病毒與肝臟發炎損傷有關。近幾年研究發現B19-VP1u的磷脂酶A2區域(phospholipase A2 motif)與B19病毒感染細胞及引起發炎反應有密切關係,但是詳細機轉仍不清楚。本篇研究利用轉染技術將VP1u蛋白表現在COS-7 細胞,經由皮下注射方式打入Balb/c小鼠並利用IVIS非侵入式活體影像系統進行觀察,探討B19-VP1u對Balb/c小鼠之影響和發炎反應分子機制。結果發現B19-VP1u會促進Balb/c小鼠肝臟基質金屬蛋白酶(MMP9)活性及蛋白表現並活化磷酸化蛋白p38和ERK及IKK-α、IκB與NF-κB訊號傳遞分子。此外,發炎相關蛋白C-Reactive Protein (CRP)、IL-1β及IL-6蛋白表現也明顯增加並透過磷酸化蛋白STAT-1訊號傳遞引起肝臟發炎損傷。由實驗結果結果顯示B19-VP1u可引發肝臟損傷的免疫致病機轉。

English Abstract

Human Parvovirus B19 is a significant human pathogen in Parvoviridae. It has been re-ported that B19 can be detected in blood or liver specimens in patient with liver diseases. Indeed, various studies have postulated a connection between B19 infection and liver injury. Recently, studies suggested that the PLA2 motif of B19-VP1u play an important role in closely associated with B19-infected and inflammatory. However, the precise mechanism is still obscure. In the present study, we aimed to investigate the influence of B19-VP1u in Balb/c mice by injected subcutaneously with COS-7 cells expressing VP1u and observed using a non-invasive IVIS bio-luminescent imaging system. Our experimental results revealed that enhanced MMP-9 activity and increased phosphorylation of p38, ERK, IKK-α, IκB and NF-κB(p65) proteins in liver from Balb/c mice receiving B19-VP1u. Additionally, significantly increased inflammatory associated proteins, including CRP, IL-1β and IL-6 were observed in liver from Balb/c mice receiving B19-VP1u. Notably, phosphorylated STAT1 proteins were involved in the induction of inflammatory cytokines in liver from Balb/c mice receiving B19-VP1u. Our findings revealed the effects of B19-VP1u on liver injury and provide a clue in understanding the role of immuno-pathogenesis of B19-VP1u.

Topic Category 醫藥衛生 > 基礎醫學
醫學院 > 生化微生物免疫研究所
Reference
  1. 1. Cossart YE, Field AM, Cant B, Widdows D: Parvovirus-like particles in human sera. Lancet 1975, 1(7898):72-73.
    連結:
  2. 2. Siegl G, Bates RC, Berns KI, Carter BJ, Kelly DC, Kurstak E, Tattersall P: Characteristics and taxonomy of Parvoviridae. Intervirology 1985, 23(2):61-73.
    連結:
  3. 3. Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, Murtaza L: Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981, 1(8221):664-665.
    連結:
  4. 4. Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, Mohamed R: Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 1981, 2(8247):595-597.
    連結:
  5. 5. Zhi N, Mills IP, Lu J, Wong S, Filippone C, Brown KE: Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. Journal of virology 2006, 80(12):5941-5950.
    連結:
  6. 6. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism 1982, 25(11):1271-1277.
    連結:
  7. 7. Cossart Y: Parvovirus B19 finds a disease. Lancet 1981, 2(8253):988-989.
    連結:
  8. 8. Zerbini M, Musiani M, Gibellini D, Gentilomi G, Venturoli S, Gallinella G, La Placa M: Evaluation of strand-specific RNA probes visualized by colorimetric and chemiluminescent reactions for the detection of B19 parvovirus DNA. Journal of virological methods 1993, 45(2):169-178.
    連結:
  9. 9. Kaufmann B, Simpson AA, Rossmann MG: The structure of human parvovirus B19. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(32):11628-11633.
    連結:
  10. 10. Bonsch C, Kempf C, Ros C: Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. Journal of virology 2008, 82(23):11784-11791.
    連結:
  11. 12. Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, Warrener P, Bansal G, Collett MS: Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. The Journal of clinical investigation 1992, 89(6):2023-2029.
    連結:
  12. 13. Kerr S, O'Keeffe G, Kilty C, Doyle S: Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. Journal of medical virology 1999, 57(2):179-185.
    連結:
  13. 15. Biagini P: Human circoviruses. Veterinary microbiology 2004, 98(2):95-101.
    連結:
  14. 16. Vihinen-Ranta M, Suikkanen S, Parrish CR: Pathways of cell infection by parvoviruses and adeno-associated viruses. Journal of virology 2004, 78(13):6709-6714.
    連結:
  15. 17. Zadori Z, Szelei J, Lacoste MC, Li Y, Gariepy S, Raymond P, Allaire M, Nabi IR, Tijssen P: A viral phospholipase A2 is required for parvovirus infectivity. Developmental cell 2001, 1(2):291-302.
    連結:
  16. 18. Abraham S, Begum S, Isenberg D: Hepatic manifestations of autoimmune rheumatic diseases. Annals of the rheumatic diseases 2004, 63(2):123-129.
    連結:
  17. 19. Corcoran A, Doyle S: Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. Journal of medical microbiology 2004, 53(Pt 6):459-475.
    連結:
  18. 20. Brown KE, Anderson SM, Young NS: Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993, 262(5130):114-117.
    連結:
  19. 21. Cooling LL, Koerner TA, Naides SJ: Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. The Journal of infectious diseases 1995, 172(5):1198-1205.
    連結:
  20. 22. Human parvovirus B19 infections in United Kingdom 1984-86. Lancet 1987, 1(8535):738-739.
    連結:
  21. 25. Watt AP, Brown M, Pathiraja M, Anbazhagan A, Coyle PV: The lack of routine surveillance of Parvovirus B19 infection in pregnancy prevents an accurate understanding of this regular cause of fetal loss and the risks posed by occupational exposure. Journal of medical microbiology 2013, 62(Pt 1):86-92.
    連結:
  22. 27. Thammasri K, Rauhamaki S, Wang L, Filippou A, Kivovich V, Marjomaki V, Naides SJ, Gilbert L: Human Parvovirus B19 Induced Apoptotic Bodies Contain Altered Self-Antigens that are Phagocytosed by Antigen Presenting Cells. PloS one 2013, 8(6):e67179.
    連結:
  23. 28. Ergaz Z, Ornoy A: Parvovirus B19 in pregnancy. Reproductive toxicology 2006, 21(4):421-435.
    連結:
  24. 29. Saarinen UM, Chorba TL, Tattersall P, Young NS, Anderson LJ, Palmer E, Coccia PF: Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986, 67(5):1411-1417.
    連結:
  25. 30. Anderson MJ, Khousam MN, Maxwell DJ, Gould SJ, Happerfield LC, Smith WJ: Human parvovirus B19 and hydrops fetalis. Lancet 1988, 1(8584):535.
    連結:
  26. 31. Enders G, Biber M: Parvovirus B19 infections in pregnancy. Behring Institute Mitteilungen 1990(85):74-78.
    連結:
  27. 32. Schwarz TF, Nerlich A, Roggendorf M: Parvovirus B19 infection in pregnancy. Behring Institute Mitteilungen 1990(85):69-73.
    連結:
  28. 33. Naides SJ: Infection with Parvovirus B19. Current infectious disease reports 1999, 1(3):273-278.
    連結:
  29. 34. Brown KE, Young NS: Parvovirus B19 in human disease. Annual review of medicine 1997, 48:59-67.
    連結:
  30. 35. MacAulay JC: Human parvovirus infection with arthropathy. The British journal of dermatology 1987, 116(6):883-884.
    連結:
  31. 36. Reid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ: Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1985, 1(8426):422-425.
    連結:
  32. 37. Lenglet T, Haroche J, Schnuriger A, Maisonobe T, Viala K, Michel Y, Chelbi F, Grabli D, Seror P, Garbarg-Chenon A et al: Mononeuropathy multiplex associated with acute parvovirus B19 infection: characteristics, treatment and outcome. Journal of neurology 2011, 258(7):1321-1326.
    連結:
  33. 39. Elena-Gonzalez A, Lozano-Duran C, Cuadros-Tito P, Gete-Garcia L: [Papular-purpuric gloves and socks syndrome and thrombocytopenia related to parvovirus B19 infection.]. Enfermedades infecciosas y microbiologia clinica 2013.
    連結:
  34. 40. Uike N, Miyamura T, Obama K, Takahira H, Sato H, Kozuru M: Parvovirus B19-associated haemophagocytosis in Evans syndrome: aplastic crisis accompanied by severe thrombocytopenia. British journal of haematology 1993, 84(3):530-532.
    連結:
  35. 41. Sakalli H, Baskin E, Bayrakci US, Melek E, Cengiz N, Ozdemir BH: Parvovirus B19-induced multisystemic vasculitis and acute endocapillary proliferative glomerulonephritis in a child. Renal failure 2010, 32(4):506-509.
    連結:
  36. 42. Delannoy D, Balquet MH, Savinel P: [Vasculitis with mixed cryoglobulin in human parvovirus B19 infection]. Presse medicale 1993, 22(4):175.
    連結:
  37. 45. Lee PC, Hung CJ, Lin YJ, Wang JR, Jan MS, Lei HY: A role for chronic parvovirus B19 infection in liver dysfunction in renal transplant recipients? Transplantation 2002, 73(10):1635-1639.
    連結:
  38. 46. Hsu TC, Chen TY, Lin MC, Tzang BS, Tsay GJ: Human parvovirus B19 infection in patients with chronic hepatitis B or hepatitis C infection. Journal of gastroenterology and hepatology 2005, 20(5):733-738.
    連結:
  39. 47. Zhang X: [Human parvovirus B19/PARV4 infection is probably associated with chronic hepatitis B/C]. Bing du xue bao = Chinese journal of virology / [bian ji, Bing du xue bao bian ji wei yuan hui] 2010, 26(2):153-157.
    連結:
  40. 48. Naides SJ, Karetnyi YV, Cooling LL, Mark RS, Langnas AN: Human parvovirus B19 infection and hepatitis. Lancet 1996, 347(9014):1563-1564.
    連結:
  41. 49. Tong R, Shen L, Yin W, Zhou W, Lu J, Zheng M, Bi S, Lou Y, Tan W: Prevalence of human parvovirus B19, bocavirus, and PARV4 in blood samples from the general population of China and lack of a correlation between parvovirus and hepatitis B co-infection. PloS one 2013, 8(5):e64391.
    連結:
  42. 50. Hsu TC, Tsai CC, Chiu CC, Hsu JD, Tzang BS: Exacerbating Effects of Human Parvovirus B19 NS1 on Liver Fibrosis in NZB/W F1 Mice. PloS one 2013, 8(6):e68393.
    連結:
  43. 51. Barton LL, Lax D, Shehab ZM, Keith JC: Congenital cardiomyopathy associated with human parvovirus B19 infection. American heart journal 1997, 133(1):131-133.
    連結:
  44. 52. Bock CT: Parvovirus B19: a new emerging pathogenic agent of inflammatory cardiomyopathy. Ernst Schering Research Foundation workshop 2006(55):83-97.
    連結:
  45. 53. Zedtwitz-Liebenstein K, Robak O, Burgmann H, Frass M: Retrospective evaluation of antibody index of human parvovirus B19 as a prognostic factor in patients with dilated and ischemic cardiomyopathy. Journal of medical virology 2013, 85(6):1111-1114.
    連結:
  46. 54. Katta R: Parvovirus B19: a review. Dermatologic clinics 2002, 20(2):333-342.
    連結:
  47. 56. Slavov SN, Haddad SK, Silva-Pinto AC, Amarilla AA, Alfonso HL, Aquino VH, Covas DT: Molecular and phylogenetic analyses of human Parvovirus B19 isolated from Brazilian patients with sickle cell disease and beta-thalassemia major and healthy blood donors. Journal of medical virology 2012, 84(10):1652-1665.
    連結:
  48. 57. Slavov SN, Kashima S, Pinto AC, Covas DT: Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS immunology and medical microbiology 2011, 62(3):247-262.
    連結:
  49. 58. Kishore J, Srivastava M, Choudhury N: Serological study on parvovirus B19 infection in multitransfused thalassemia major patients and its transmission through donor units. Asian journal of transfusion science 2011, 5(2):140-143.
    連結:
  50. 59. Bergallo M, Merlino C, Daniele R, Costa C, Ponzi AN, Cavallo R: Quantitative competitive-PCR assay to measure human parvovirus B19-DNA load in serum samples. Molecular biotechnology 2006, 32(1):23-29.
    連結:
  51. 60. Patou G, Pillay D, Myint S, Pattison J: Characterization of a nested polymerase chain reaction assay for detection of parvovirus B19. Journal of clinical microbiology 1993, 31(3):540-546.
    連結:
  52. 61. Pereira RF, Paula WN, Cubel Rde C, Nascimento JP: Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection. Memorias do Instituto Oswaldo Cruz 2001, 96(4):507-513.
    連結:
  53. 62. Gray JJ, Cohen BJ, Desselberger U: Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity. Journal of virological methods 1993, 44(1):11-23.
    連結:
  54. 63. Beersma MF, Claas EC, Sopaheluakan T, Kroes AC: Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005, 34(1):71-75.
    連結:
  55. 64. von Poblotzki A, Gigler A, Lang B, Wolf H, Modrow S: Antibodies to parvovirus B19 NS-1 protein in infected individuals. The Journal of general virology 1995, 76 ( Pt 3):519-527.
    連結:
  56. 65. Erythema infectionvon Poblotzki A, Hemauer A, Gigler A, Puchhammer-Stockl E, Heinz FX, Pont J, Laczika K, Wolf H, Modrow S: Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. The Journal of infectious diseases 1995, 172(5):1356-1359.
    連結:
  57. 67. Yang SH, Lin LW, Fang YJ, Cheng AL, Kuo SH: Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma. Annals of hematology 2012, 91(2):291-294.
    連結:
  58. 68. Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E: Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transplant infectious disease : an official journal of the Transplantation Society 2013.
    連結:
  59. 70. Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, Wong S, Shelly D, Young NS, Dempsey W: Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011, 29(43):7357-7363.
    連結:
  60. 71. Fasano C, Kanduc D: Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine. Self/nonself 2011, 2(2):114-119.
    連結:
  61. 73. Saikawa T, Anderson S, Momoeda M, Kajigaya S, Young NS: Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. Journal of virology 1993, 67(6):3004-3009.
    連結:
  62. 74. Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, Kakkola L, Soderlund-Venermo M, Young NS, Brown KE: VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 2008, 374(2):444-452.
    連結:
  63. 75. Heegaard ED, Qvortrup K, Christensen J: Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: serologic cross-reactivity with erythrovirus B19. Journal of medical virology 2002, 66(2):246-252.
    連結:
  64. 76. Yavin EJ, Fridkin M: Peptides derived from human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and cathepsin G: use of overlapping peptide sequences to identify a unique inhibitor. The journal of peptide research : official journal of the American Peptide Society 1998, 51(4):282-289.
    連結:
  65. 77. Deng X, Dong Y, Yi Q, Huang Y, Zhao D, Yang Y, Tijssen P, Qiu J, Liu K, Li Y: The determinants for the enzyme activity of human parvovirus B19 phospholipase A2 (PLA2) and its influence on cultured cells. PloS one 2013, 8(4):e61440.
    連結:
  66. 78. Lu J, Zhi N, Wong S, Brown KE: Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. The Journal of infectious diseases 2006, 193(4):582-590.
    連結:
  67. 79. Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, Hsu TC: The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production. Clinica chimica acta; international journal of clinical chemistry 2007, 378(1-2):59-65.
    連結:
  68. 80. Tsai CC, Tzang BS, Chiang SY, Hsu GJ, Hsu TC: Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. Journal of biomedical science 2009, 16:14.
    連結:
  69. 81. Vu TH, Werb Z: Matrix metalloproteinases: effectors of development and normal physiology. Genes & development 2000, 14(17):2123-2133.
    連結:
  70. 82. Ram M, Sherer Y, Shoenfeld Y: Matrix metalloproteinase-9 and autoimmune diseases. Journal of clinical immunology 2006, 26(4):299-307.
    連結:
  71. 83. Luo Y, Liang F, Zhang ZY: PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009, 48(8):1838-1846.
    連結:
  72. 84. Onodera M, Zen Y, Harada K, Sato Y, Ikeda H, Itatsu K, Sato H, Ohta T, Asaka M, Nakanuma Y: Fascin is involved in tumor necrosis factor-alpha-dependent production of MMP9 in cholangiocarcinoma. Laboratory investigation; a journal of technical methods and pathology 2009, 89(11):1261-1274.
    連結:
  73. 85. Tzang BS, Lin TM, Tsai CC, Hsu JD, Yang LC, Hsu TC: Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. Molecular immunology 2011, 48(12-13):1518-1524.
    連結:
  74. 87. Sun Z, Andersson R: NF-kappaB activation and inhibition: a review. Shock 2002, 18(2):99-106.
    連結:
  75. 88. Lu Y, Wahl LM: Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. Journal of leukocyte biology 2005, 78(1):259-265.
    連結:
  76. 90. Bek KM, Nielsen FR, Qvist I, Rasmussen PE, Tobiassen M: C-reactive protein (CRP) and pregnancy. An early indicator of chorioamnionitis. A review. European journal of obstetrics, gynecology, and reproductive biology 1990, 35(1):29-33.
    連結:
  77. 91. Di Napoli M, Elkind MS, Godoy DA, Singh P, Papa F, Popa-Wagner A: Role of C-reactive protein in cerebrovascular disease: a critical review. Expert review of cardiovascular therapy 2011, 9(12):1565-1584.
    連結:
  78. 92. Marnell L, Mold C, Du Clos TW: C-reactive protein: ligands, receptors and role in inflammation. Clinical immunology 2005, 117(2):104-111.
    連結:
  79. 93. Volanakis JE: Human C-reactive protein: expression, structure, and function. Molecular immunology 2001, 38(2-3):189-197.
    連結:
  80. 94. Ozmen MM, Zulfikaroglu B, Col C, Cinel I, Isman FK, Cinel L, Besler TH: Effect of increased abdominal pressure on cytokines (IL1 beta, IL6, TNFalpha), C-reactive protein (CRP), free radicals (NO, MDA), and histology. Surgical laparoscopy, endoscopy & percutaneous techniques 2009, 19(2):142-147.
    連結:
  81. 95. Oleksowicz L, Dutcher JP: A Review of the New Cytokines: IL-4, IL-6, IL-11, and IL-12. American journal of therapeutics 1994, 1(2):107-115.
    連結:
  82. 96. Knupfer H, Preiss R: Significance of interleukin-6 (IL-6) in breast cancer (review). Breast cancer research and treatment 2007, 102(2):129-135.
    連結:
  83. 97. Peluso I, Raguzzini A, Serafini M: Effect of flavonoids on circulating levels of TNF-alpha and IL-6 in humans: a systematic review and meta-analysis. Molecular nutrition & food research 2013, 57(5):784-801.
    連結:
  84. 98. Coffer PJ, Kruijer W: EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochemical and biophysical research communications 1995, 210(1):74-81.
    連結:
  85. 99. Horvath CM, Stark GR, Kerr IM, Darnell JE, Jr.: Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Molecular and cellular biology 1996, 16(12):6957-6964.
    連結:
  86. 100. Janjua S, Stephanou A, Latchman DS: The C-terminal activation domain of the STAT-1 transcription factor is necessary and sufficient for stress-induced apoptosis. Cell death and differentiation 2002, 9(10):1140-1146.
    連結:
  87. 101. Siewert E, Muller-Esterl W, Starr R, Heinrich PC, Schaper F: Different protein turnover of interleukin-6-type cytokine signalling components. European journal of biochemistry / FEBS 1999, 265(1):251-257.
    連結:
  88. 102. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. The Biochemical journal 1998, 334 ( Pt 2):297-314.
    連結:
  89. 103. Is'harc H, Watling D, Kerr IM: Phosphotyrosine profiling to identify novel components of interferon and interleukin 6-family cytokine signalling. Proteomics 2001, 1(6):767-772.
    連結:
  90. 104. Himpe E, Kooijman R: Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway. BioFactors 2009, 35(1):76-81.
    連結:
  91. 105. Joshi VD, Kalvakolanu DV, Chen W, Zhang L, Kang TJ, Thomas KE, Vogel SN, Cross AS: A role for Stat1 in the regulation of lipopolysaccharide-induced interleukin-1beta expression. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2006, 26(10):739-747.
    連結:
  92. 106. Aida Y, Maeno M, Suzuki N, Namba A, Motohashi M, Matsumoto M, Makimura M, Matsumura H: The effect of IL-1beta on the expression of inflammatory cytokines and their receptors in human chondrocytes. Life sciences 2006, 79(8):764-771.
    連結:
  93. 108. Tzang BS, Chiu CC, Tsai CC, Lee YJ, Lu IJ, Shi JY, Hsu TC: Effects of human parvovirus B19 VP1 unique region protein on macrophage responses. Journal of biomedical science 2009, 16:13.
    連結:
  94. 11. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR: Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. Journal of virology 1986, 58(3):921-936.
  95. 14. Sol N, Le Junter J, Vassias I, Freyssinier JM, Thomas A, Prigent AF, Rudkin BB, Fichelson S, Morinet F: Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. Journal of virology 1999, 73(10):8762-8770.
  96. 23. Rivier G, Gerster JC, Terrier P, Cheseaux JJ: Parvovirus B19 associated monoarthritis in a 5-year-old boy. The Journal of rheumatology 1995, 22(4):766-767.
  97. 24. Servey JT, Reamy BV, Hodge J: Clinical presentations of parvovirus B19 infection. American family physician 2007, 75(3):373-376.
  98. 26. Lacaze T, de Prost Y, Lefrere JJ, Courouce AM: [Parvovirus B19 and the fifth disease]. Archives francaises de pediatrie 1987, 44(8):619-620.
  99. 38. Frotscher B, Salignac S, Morlon L, Bonmati C, Jeulin H, Venard V, Lecompte T: [Neutropenia and/or thrombocytopenia due to acute parvovirus B19 infection]. Annales de biologie clinique 2009, 67(3):343-348.
  100. 43. Engel F, Maradeix S, Braun-Parvez L, Lipsker D, Cribier B: [Leukocytoclastic vasculitis with severe renal involvement following Parvovirus B19 primary infection]. Annales de dermatologie et de venereologie 2007, 134(2):160-163.
  101. 44. Bihari C, Rastogi A, Rangegowda D, Chowdhury A, Saxena P, Garg H, Sarin SK: Parvovirus B19 associated acute hepatitis and hepatosplenomegaly. Clinics and research in hepatology and gastroenterology 2013.
  102. 55. Morel O, Chagnaud S, Laperrelle J, Clement D, Malartic C, Akerman G, Tulpin L, Sitbon M, Barranger E: [Parvovirus B19 in pregnancy: literature review]. Gynecologie, obstetrique & fertilite 2007, 35(11):1095-1104.
  103. 66. Morinet F: [Fetal erythropoiesis and parvovirus B19]. Pathologie-biologie 1992, 40(7):711-713.
  104. 69. Broliden K: [Parvovirus B19 infection--a risk factor during pregnancy. Asymptomatic course of disease makes the prevention and treatment more difficult]. Lakartidningen 2003, 100(4):222-224.
  105. 72. Goret P, Pilet C: [Vaccination of cattle with B19 vaccine and similar vaccines]. Annales de l'Institut Pasteur 1962, 102:774-791.
  106. 86. Yorsangsukkamol J, Chaiprasert A, Palaga T, Prammananan T, Faksri K, Palittapongarnpim P, Prayoonwiwat N: Apoptosis, production of MMP9, VEGF, TNF-alpha and intracellular growth of M. tuberculosis for different genotypes and different pks5/1 genes. Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand 2011, 29(3):240-251.
  107. 89. Wang Y, Li de L, Zhang XB, Duan YH, Wu ZH, Hao DS, Chen BS, Qiu GX: Increase of TNFalpha-stimulated osteoarthritic chondrocytes apoptosis and decrease of matrix metalloproteinases 9 by NF-kappaB inhibition. Biomedical and environmental sciences : BES 2013, 26(4):277-283.
  108. 107. Karakoc D, Sayek I: Effect of peritoneal lavage on TNF-alpha, IL-1beta, and IL-6 levels and mortality in intraabdominal infections. International surgery 2008, 93(6):346-353.